# A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

> **NCT06681766** · PHASE1 · TERMINATED · sponsor: **Larimar Therapeutics, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Friedreich Ataxia

## Interventions

- **DRUG:** Nomlabofusp
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06681766
- **Lead sponsor:** Larimar Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-12-06
- **Primary completion:** 2025-04-28
- **Final completion:** 2025-04-28
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Review of Cohort 1 data facilitated direct enrollment into open label study and eliminate pause in study drug administration between PK study and open label study.
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06681766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06681766, "A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06681766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*